Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

884 - Durable response to cetuximab plus FOXFOX in metastatic unresectable sigmoid colon cancer


24 Nov 2018


Poster display - Cocktail


Tumour Site

Colon and Rectal Cancer


Dheeravee Ratanapichayachai


D. Ratanapichayachai

Author affiliations

  • Medicine, Faculty of Medicine Siriraj Hospital, 10700 - Bangkok/TH


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 884

Case Summary

A 52-year-old man was diagnosed of stage 3 sigmoid colon cancer in December 2007. He was incidentally found to have iron deficiency anemia on preoperative evaluation for gluteal abscess. Colonoscopy revealed a polypoid mass at sigmoid colon. He underwent sigmoidectomy which pathology report demonstrated moderately differentiated adenocarcinoma invading into subserosa with 7 positive lymph nodes (pT3N2bM0). All surgical resected margins were free. He received 6-cycle of adjuvant bolus 5FU/leucovorin. He was doing well with normalized serum CEA postoperatively.

In May 2009, serum CEA rose to 34 ng/ml and abdominal CT showed enhancing liver masses at segment 2 and segment 6 sized 4.9 cm and 2.8 cm, respectively. Also, peripancreatic, mesenteric and retrocaval lymph nodes sized up to 3.2 cm were found. Metastatic unresectable wild-type RAS sigmoid colon cancer was diagnosed. He received palliative FOLFOX-6 plus cetuximab 500 mg/m2 every 14 days. At 2 months after starting treatment, thoracic and abdominal CT demonstrated partial response with 59% reduction of target lesions. Subsequent CT scan showed ongoing response. Oxaliplatin was discontinued after 14th cycle of treatment due to grade 3 neuropathy which was subsequently resolved. Cetuximab with infusional 5FU/ leucovorin was continued to the total of 103 cycles and then cetuximab every 2 weeks was maintained until present. The latest CT in July 2018 showed a 1.2 cm non-enhancing liver lesion with subcentimeter lymph nodes. The patient is doing well with occasional grade 1 skin rash.

We reported an unusual, unexpected response to chemotherapy plus anti-EGFR in a patient with metastatic unresectable colon cancer. Further molecular testing might be useful to determine unidentified potential prognostic or predictive factor in such an extreme case.

Editorial acknowledgement

Clinical trial identification

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.